WuXi PharmaTech Cayman Inc

Type: Company
Name: WuXi PharmaTech Cayman Inc (WuXi PharmaTech (Cayman) Inc)
First reported Oct 01 2014 - Updated 6 hours ago - 5 reports

WuXi PharmaTech expands in US with acquisition of XenoBiotic Laboratories

rmaceutical company WuXi PharmaTech, has expanded its laboratory testing division in the US with the acquisition of contract research organisation XenoBiotic Laboratories (XBL).XBL provides bioanalytical, drug metabolism and pharmacokinetic services to ... [Published Manufacturing Chemist - 6 hours ago]
First reported Sep 30 2014 - Updated Oct 01 2014 - 4 reports

WuXi PharmaTech elects William R. Keller to board

Pharmaceutical company WuXi PharmaTech (Cayman) (NYSE:WX) revealed on Tuesday the addition of William Robert Keller as an independent director of its board of directors as well as the Strategy Committee. Currently, Keller is a director at Alexion Pharmaceuticals ... [Published Individual.com - Oct 01 2014]
First reported Sep 25 2014 - Updated Sep 26 2014 - 3 reports

Zacks Investment Ideas feature highlights: NQ Mobile, WuXi PharmaTech and Amazon

CHICAGO, Sept. 26, 2014 /PRNewswire/ -- Today, Zacks Investment Ideas feature highlights Features: NQ Mobile (NYSE:NQ-Free Report), WuXi PharmaTech (NYSE:WX-Free Report) and Amazon (Nasdaq:AMZN-Free Report). A Nefarious Quandary: The NQ SagaAs a writer ... [Published PR Newswire: Financial Services - Sep 26 2014]
First reported Sep 23 2014 - Updated Sep 24 2014 - 2 reports

Upgrade Alert for WuXi PharmaTech Cayman (WX)

WuXi PharmaTech Cayman (NYSE:WX) was upgraded from Neutral to Conviction Buy at Goldman Sachs today. The stock closed yesterday at $33.88 on volume of 142,000 shares, below average daily volume of 378,000. WuXi PharmaTech Cayman Inc. provides pharmaceutical ... [Published Individual.com - Sep 24 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Asian ADRs Lower Despite Renewable Energy Gains

In Southern Asia, business process management company WNS Holdings ( WNS ) was trading 1.3% lower and Indian news and shopping web portal Rediff.com India (REDF) was down 1.2%. while SIFY (SIFY), an integrated network and electronic commerce services ... [Published Nasdaq - Sep 22 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 2 reports

Avelas Biosciences Extends Series B Financing to $7.4 Million

Avelas Biosciences, an in vivo cancer diagnostic company for oncologic surgeries, announced that it has closed on the second tranche of its Series B financing bringing the total funds raised in the round to $7.4 million. Participants in the financing ... [Published PE Hub Blog - Sep 10 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Eye on WuXi PharmaTech (Cayman) Inc. (WX)

(AdviceTrade via COMTEX News Network) -- by Sinisa Persic, www.TraderHRan AdviceTrade.com publicationWuXi PharmaTech (Cayman) Inc. (WX) is positioned to break out of a two-week flag that has been a rest period after it ran up more than 10% in mid Aug ... [Published PredictWallStreet - Sep 03 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 7 reports

Aldea Pharmaceuticals Takes $24M

Redwood City-based Aldea Pharmaceuticals said this morning that it has raised $24M in a Series B funding round. The funding came from RusnanoMedInvest (RMI) and WuXi PharmaTech Corporate Ventures, along with prior investors Canaan Partners and Correlation ... [Published Silicontap - Aug 25 2014]
First reported Aug 14 2014 - Updated Aug 15 2014 - 1 reports

Stocks On the Move: Red Robin Gourmet Burgers, Inc., Vertex Energy Inc, and WuXi PharmaTech (Cayman) Inc. (ADR)

In afternoon trading, three of the top market movers are restaurant chain Red Robin Gourmet Burgers, Inc. (NASDAQ:RRGB, environmental services firm Vertex Energy Inc (NASDAQ:VTNR), and Chinese pharmaceutical issue WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE:WX). ... [Published Schaeffers Research - Aug 14 2014]
First reported Aug 13 2014 - Updated Aug 14 2014 - 1 reports

WuXi PharmaTech Announces Second-Quarter 2014 Results

SHANGHAI, Aug. 13, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development services company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, ... [Published PR Newswire: Financial Services - Aug 13 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

WuXi PharmaTech Announces Appointment of Walter Kwauk to Board

SHANGHAI, Aug. 8, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced the appointment of Walter ... [Published PR Newswire: General Business - Aug 08 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release

SHANGHAI, July 22, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial ... [Published PR Newswire: Health - Jul 22 2014]

Quotes

"Dr Wu has spent the past 27 years building a solid organisation and reputation within the industry. This business combination is an important step in WuXi's development of a comprehensive, integrated platform of R&D services to help our customers discover and develop drugs more efficiently and cost-effectively."
...industry," said Dr Jinn Wu, president and chief executive Officer, XBL, who has been appointed Vice President and Chief Scientific Officer of LTD. "We will continue to provide our services to our current clients while also offering expanded services to WuXi's clients."
"I am delighted to join the board of WuXi PharmaTech, the leading China"
"We are very pleased to welcome Mr. Keller to WuXi's board," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "His wealth of experience as an executive director, and consultant in the pharmaceutical industry, both globally and in China, will be valuable as WuXi continues to build a comprehensive, integrated platform of services for our global life science customers."

More Content

All (77) | News (41) | Reports (0) | Blogs (25) | Audio/Video (0) | Fact Sheets (2) | Press Releases (9)
sort by: Date | Relevance
WuXi PharmaTech expands in US with acquisition ... [Published Manufacturing Chemist - 6 hours ago]
WuXi acquires US based CRO [Published Bio Spectrum Asia - 11 hours ago]
WuXi PharmaTech acquires XenoBiotic Laboratories [Published Center Watch - 18 hours ago]
WuXi PharmaTech acquires XenoBiotic Labs [Published Pharma Letter - Oct 01 2014]
WuXi PharmaTech Acquires XenoBiotic Labs [Published Contract Pharma - Oct 01 2014]
WuXi PharmaTech elects William R. Keller to board [Published Individual.com - Oct 01 2014]
WuXi PharmaTech Laboratory Testing Division Exp... [Published Financial Services - Oct 01 2014]
Biggest Movers in Healthcare Stocks Now – ICUI ... [Published InvestorPlace.com - Sep 30 2014]
WuXi PharmaTech Announces Appointment of Willia... [Published Stock Nod - Sep 30 2014]
WuXi PharmaTech Cayman : Announces Appointment ... [Published 4 Traders - Sep 30 2014]
WuXi PharmaTech Announces Appointment of Willia... [Published PR Newswire: General Business - Sep 30 2014]
Zacks Investment Ideas feature highlights: NQ M... [Published PR Newswire: Financial Services - Sep 26 2014]
Biggest Movers in Healthcare Stocks Now – ENDP ... [Published InvestorPlace.com - Sep 25 2014]
Shares of WuXi PharmaTech Cayman Under P... [Published Financial News Network online - Sep 25 2014]
Shares of WuXi PharmaTech Cayman Under Pressure... [Published Individual.com - Sep 25 2014]
Biggest Movers in Healthcare Stocks Now – ACOR ... [Published InvestorPlace.com - Sep 24 2014]
Upgrade Alert for WuXi PharmaTech Cayman (WX) [Published Individual.com - Sep 24 2014]
Avelas Biosciences completes $7.4M funding [Published U-T San Diego - Sep 24 2014]
WuXi PharmaTech Raised to Conviction-Buy at Gol... [Published American Banking News - Stock Ratings - Sep 23 2014]
HPAPIs and Cytotoxic Drugs Manufacturing Market... [Published Nation's Restaurant News - Sep 23 2014]
Asian ADRs Lower Despite Renewable Energy Gains [Published Nasdaq - Sep 22 2014]
Biggest Movers in Healthcare Stocks Now – CLVS ... [Published InvestorPlace.com - Sep 18 2014]
Avelas Biosciences Raises $7.4M in Funding Round [Published San Diego Business Journal - Sep 10 2014]
Avelas Biosciences Extends Series B Financing t... [Published PE Hub Blog - Sep 10 2014]
Healthcare Industry Consolidation: The Rise Of ... [Published Seeking Alpha - Sep 10 2014]
Avelas Closes Round, Advancing Biologic That Il... [Published Xconomy - Sep 10 2014]
Avelas Biosciences Boosts Series B to $7.4M [Published Dow Jones Financial Information Services - Sep 10 2014]
Hottest Healthcare Stocks Now – PTCT NPSP UTHR OPK [Published InvestorPlace.com - Sep 09 2014]
Eye on WuXi PharmaTech (Cayman) Inc. (WX) [Published PredictWallStreet - Sep 03 2014]
Russian VC invests in U.S. aldehyde metabolism ... [Published Marchmont.ru - Sep 01 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
WuXi PharmaTech Announces Appointment of Willia... [Published PR Newswire: General Business - Sep 30 2014]
SHANGHAI, Sept. 30, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced the appointment of William ...
Zacks Investment Ideas feature highlights: NQ M... [Published PR Newswire: Financial Services - Sep 26 2014]
CHICAGO, Sept. 26, 2014 /PRNewswire/ -- Today, Zacks Investment Ideas feature highlights Features: NQ Mobile (NYSE:NQ-Free Report), WuXi PharmaTech (NYSE:WX-Free Report) and Amazon (Nasdaq:AMZN-Free Report). A Nefarious Quandary: The NQ SagaAs a writer ...
Avelas Biosciences Extends Series B Financing t... [Published PE Hub Blog - Sep 10 2014]
Avelas Biosciences, an in vivo cancer diagnostic company for oncologic surgeries, announced that it has closed on the second tranche of its Series B financing bringing the total funds raised in the round to $7.4 million. Participants in the financing ...
The Daily Startup: Pre-VC Rounds Shaking Up Ear... [Published WSJ.com: Venture Capital Dispatch - Aug 25 2014]
The $99 Sense sleep tracking device has been backed by angel investors and crowdfunding campaigns so far.Hello Startups are tapping new sources of early-stage funding, including ad hoc networks of wealthy tech executives doing some investing on the side, ...
Aldea Pharmaceuticals snags $24 mln Series B [Published PE Hub Blog - Aug 25 2014]
Aldea Pharmaceuticals said Monday that it has received $24 million in Series B financing. The investors included RusnanoMedInvest, WuXi PharmaTech Corporate Ventures, Canaan Partners and Correlation Ventures. Based in Redwood City, Calif., Aldea ...
1 2 3 4 5

Press Releases

sort by: Date | Relevance
WuXi PharmaTech Laboratory Testing Division Exp... [Published Financial Services - Oct 01 2014]
Scheduled Conference Calls and Managements Chan... [Published Financial Services - Jul 14 2014]
Collaborations, Clinical Study Results, and Lab... [Published Financial Services - Jun 25 2014]
Health Care Sector Stocks Coverage -- Research ... [Published Financial Services - Jun 18 2014]
Strategic Collaborations, Certified Solutions, ... [Published Financial Services - Jun 05 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.